Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats

NeuroReport

Volumn 16, Issue 15, 2005, Pages 1683-1686

  Dizgah, Iraj Mirzaii ^a   Karimian, Seyed Morteza ^a   Zarrindast, Mohammad Reza ^a   Sohanaki, Hamid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Locus coeruleus; Morphine; Naloxone; Rat; SCH23390; SKF38393; Withdrawal

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MORPHINE; NALOXONE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; LOCUS CERULEUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; STATISTICAL ANALYSIS; WITHDRAWAL SYNDROME;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; 2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; INJECTIONS; LOCUS COERULEUS; MALE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 29144458846     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnr.0000180142.91644.65     Document Type: Article

References (24)

1. Sklair-Tavron L, Shi WX, Lane SB, Harris HW, Bunney BS, Nestler EJ. Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons. Proc Natl Acad Sci USA 1996; 93:11202-11207.
2. Georges F, Stinus L, Bloch B, Le Moine C. Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur J Neurosci 1999; 11:481-490.
3. Ahtee L, Attila LMJ, Carlson KR, Haikala H. Changes in brain monoamine metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge in the withdrawn state. J Pharmacol Exp Ther 1989; 249:303-310.
4. Zarrindast MR, Zarghi A. Morphine stimulates locomotor activity by an indirect dopaminergic mechanism: possible D-1 and D-2 receptor involvement. Gen Pharmacol 1992; 23:1221-1225.
5. Zarrindast MR, Vahedy A, Heidari MR, Ghazi-Khansari M. On the mechanism(s) of morphine-induced hypothermia. J Psychopharmacol 1994; 8:222-226.
6. Zarrindast MR, Mamanpush SM, Rashidy-pour A. Morphine inhibits dopaminergic and cholinergic induced ejaculation in rats. Gen Pharmacol 1994; 25:803-808.
7. Harris G, Aston-Jones G. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 1994; 371:155-157.
8. Zarrindast MR, Habibi M, Borzabadi S, Fazli-Tabaei S, Yahyavi SH, Rostamin P. The effects of dopamine receptor agents on naloxone-induced jumping behavior in morphine-dependent mice. Eur J Pharmacol 2002; 451:287-293.
9. Maldonado R, Stinus L, Koob GF. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 1992; 261:669-677.
10. Versteeg DHG, Van der Gugten J, De Jong W, Palkovits M. Regional concentrations of noradrenaline and dopamine in rat brain. Brain Res 1976; 113:563-574.
11. Ornstein K, Milon H, McRae-Deguerce A, Alvarez C, Berger B, Wurzner HP. Biochemical and radioautographic evidence for dopaminergic afferents of the locus coeruleus originating in the ventral tegmental area. J Neural Trans 1987; 70:183-191.
12. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Academic Press: New York; 1986.
13. Zarrindast MR, Nasehi M, Rostami P, Rezayof A, Fazli-Tabaei S. Repeated administration of dopaminergic agents in the dorsal hippocampus and morphine-induced place preference. Behav Pharmacol 2005; 16:85-92.
14. Yang YR, Lee EHY, Chiu TH. Electrophysiological and behavioral effects of Tyr-D-Arg-Phe-Sar on locus coeruleus neurons of the rat. Eur J Pharmacol 1998; 351:23-30.
15. Rasmussen K, Hsu MA, Vandergriff J. The selective mGlu2/3receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal induced activation of locus coeruleus neurons. Neuropharmacology 2004; 46:620-628.
16. Woldbye DP, Klemp K, Madsen TM. Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors. J Pharmacol Exp Ther 1998; 284:633-636.
17. Espejo EF, Cador M, Stinus L. Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: A newly-developed 'etho-score.' Psychopharmacology 1995; 122:122-130.
18. Verma A, Kulkarni SK. Role of D1 /D2 dopamine and N-methyl-D-aspartate (NMDA) receptors in morphine tolerance and dependence in mice. Eur Neuropsychopharmacol 1995; 5:81-87.
19. Kebabian JW, Calne DB. Multiple receptors of dopamine. Nature 1979; 227:93-96.
20. Nestler EJ, Tallman JF. Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol Pharmacol 1988; 33:127-132.
21. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74:1-57.
22. Lin JY, Dubey R, Funk GD, Lipski J. Receptor subtype-specific modulation by dopamine of glutamatergic responses in striatal medium spiny neurons. Brain Res 2003; 959:251-262.
23. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 2002; 111:219-230.
24. Tokuyama S, Zhu Y, Oh S, Ho IK, Yamamot T. Further evidence for a role of NMDA receptors in the locus coeruleus in the expression of withdrawal syndrome from opioids. Neurochem Int 2001; 39:103-109.